



Cite this: *Org. Biomol. Chem.*, 2024, **22**, 5948

Synthesis of fluorinated curcumin derivatives for detecting amyloid plaques by ^{19}F -MRI†

Sebastiano Micocci,^{‡,a} Rachele Stefania,^{‡,*,b} Francesca Garello,^{‡,a} Umberto Fasoglio,^a Ivan Hawala,^{‡,a} Lorenzo Tei,^{‡,b} Simonetta Geninatti Crich,^{‡,a} and Giuseppe Digilio^b

The most prominent pathophysiological hallmark of Alzheimer's disease is the aggregation of amyloid- β (A β) peptides into senile plaques. Curcumin and its derivatives exhibit a high affinity for binding to A β fibrils, effectively inhibiting their growth. This property holds promise for both therapeutic applications and diagnostic molecular imaging. In this study, curcumin was functionalized with perfluoro-*tert*-butyl groups to create candidate molecular probes specifically targeted to A β fibrils for use in ^{19}F -magnetic resonance imaging. Two types of fluorinated derivatives were considered: mono-substituted (containing nine fluorine atoms per molecule) and disubstituted (containing eighteen fluorine atoms). The linker connecting the perfluoro moiety with the curcumin scaffold was evaluated for its impact on binding affinity and water solubility. All mono-substituted compounds and one disubstituted compound exhibited a binding affinity toward A β fibrils on the same order of magnitude as reference curcumin. The insertion of a charged carboxylate group into the linker enhanced the water solubility of the probes. Compound **Curc-Glu-F9** (with one L-glutamyl moiety and a perfluoro-*tert*-butyl group), showed the best properties in terms of binding affinity towards A β fibrils, water solubility, and intensity of the ^{19}F -NMR signal in the A β oligomer bound form.

Received 6th May 2024,
Accepted 2nd July 2024

DOI: 10.1039/d4ob00730a

rsc.li/obc

Introduction

Alzheimer's disease (AD) is characterized by a progression from episodic memory problems to a slow global decline in cognitive function. The scientific research in the field is focused on the investigation of a simple and accurate way to detect Alzheimer's before these devastating symptoms begin. Cerebral amyloid-beta (A β) accumulation and aggregation is the primary event in AD pathogenesis.^{1a,b} It has been proposed that the rest of the disease process, including the formation of neurofibrillary tangles containing tau protein, results from an imbalance between A β production and A β clearance.^{2a,b} Accordingly, estimating the level of A β deposition in the brain would be informative for early diagnosis of AD and for evaluating AD progression. Among the various aggregates that A β can generate, oligomers gather during the early phases of A β aggre-

gation and have the most neurotoxic effects.^{2a,3} Larger aggregates, such as protofibrils and fibrils, can fragmentate, releasing them and acting as sinks. In order to achieve early detection of A β oligomers and protofibrils, many researchers have tried to develop chemical probes that have a specific affinity for A β aggregates. Compounds able to bind selectively with high affinity the A β aggregates *in vitro* and *in vivo* are derivatives based on highly conjugated aromatic systems, such as thioflavin T, Congo red, chrysamine G, benzoxazoles, curcumin, and stilbenes.⁴ Among them, curcumin is of great interest because it is food-derived and shows a superior safety profile. Curcumin is a low molecular weight yellow-orange pigment derived from the turmeric plant with numerous pharmacological properties including anti-tumor, anti-oxidative, anti-inflammatory, hepatoprotective, nephroprotective, and anti-amyloid effects. Several studies have reported that curcumin has a high binding affinity to A β aggregates and inhibits the aggregation.⁵ Structurally, curcumin contains two methoxyphenol rings linked by a conjugated diene- β -dicarbonyl backbone. Curcumin is a potentially great scaffold to develop probes for A β diagnostic imaging and/or therapy because of its blood-brain barrier (BBB) permeability, high-affinity binding to senile plaques, and low toxicity.⁶ Curcumin is also reported to reduce A β aggregates in Alzheimer's transgenic mice.⁷ Considerable progress in A β

^aDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, 10126 Torino, Italy

^bDepartment of Science and Technological Innovation, University of Eastern Piedmont "Amedeo Avogadro", Viale Teresa Michel 11, 15120 Alessandria, Italy.
E-mail: rachele.stefania@uniupo.it

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ob00730a>

‡These authors contributed equally.



imaging has been achieved in recent years.⁸ Currently, positron emission tomography (PET) is the most efficient imaging modality to detect A β deposition because of its high sensitivity and the ability to quantify the accumulated probe. Pittsburgh compound B ([¹¹C]PiB), which is a derivative of thioflavin (Th-T), was the first successful A β -selective PET radioligand;⁹ then, different ¹⁸F-labeled A β -targeting derivatives emerged to overcome the 20 min radioactive decay half-life limitation of ¹¹C-PiB.^{10,11a,b} Magnetic resonance imaging (MRI) is another important and widely clinically used diagnostic technique that provides detailed anatomical information with excellent soft tissue contrast, and it is amenable to molecular imaging applications provided that suitable MRI probes are available. MRI probes are typically based on paramagnetic contrast agents, but diamagnetic probes carrying the MR active ¹⁹F nuclei are attracting a growing interest because of several advantages: first, the ¹⁹F nucleus has a high gyromagnetic ratio and a natural isotopic abundance of 100%, hence an MR sensitivity approaching that of ¹H. Second, biological tissues contain essentially no ¹⁹F: only negligible amounts of endogenous fluorine are embedded in the teeth and bone matrix of the human body. Therefore, the introduction of exogenous ¹⁹F signals *in vivo* will yield background-free images. Third, ¹⁹F MRI exhibits relatively high spatial resolution. In addition, it is worth noting that ¹⁹F is a naturally occurring halogen and a stable, non-radioactive isotope of fluorine. Thus, unlike the radioactive isotope ¹⁸F commonly used in PET imaging, incorporating fluorine into a probe is synthetically smoother. Yanagisawa *et al.* developed the first perfluoro curcumin analogue, FMeC1,¹² for ¹⁹F MRI to facilitate visualization of A β *in vivo*. FMeC1, named then Shiga-Y5, containing two trifluoromethoxy groups in place of the methoxy ones and a methylpropanoate moiety on the C4 position (Fig. 1), could cross the blood-brain barrier and bind to A β plaques in a transgenic mouse model of AD after injection *via* the tail vein. They also developed and investigated several ¹⁹F-containing curcumin analogue, called the Shiga-Y series, with different moieties at the C4 position;¹³ among them, Shiga-Y25 (Fig. 1) with a short PEG chain ending with a trifluoromethoxy group successfully detected A β depositions in the brain of a living mouse.¹⁴ All

developed probes contained a limited number of ¹⁹F atoms/molecule, typically six/molecule, except the case of Shiga-Y25 which contains nine ¹⁹F atoms.

This work aims at synthesizing a series of novel ¹⁹F-containing curcumins with a high number of equivalent ¹⁹F nuclei, suitably spaced from the aromatic part of the molecule. Furthermore, we present a novel synthetic approach that involves direct modification of the OH group attached to the phenol moiety of curcumin to produce novel ¹⁹F curcumin derivatives (**Curc-C₃-F9**, **Curc-C₆-F9**, **Curc-Glu-F9**, **Curc-C₆-F18**, **Curc-Glu-F18**). The affinity of the novel derivatives for A β fibrils was evaluated *in vitro* by a fluorescence-based assay, and the ¹⁹F-NMR properties in the fibril-bound state were investigated *in vitro*.

Results and discussion

Design of the ¹⁹F-curcumin imaging probes

Several aspects must be kept into account when designing curcumin-based ¹⁹F-MRI probes targeted to A β fibrils. The enol form of these compounds must be preserved as it shows preference for binding to A β fibrils,¹⁵ whereas the keto form favours the binding to A β oligomers.¹⁶ Another important parameter to consider is the hydrophilicity/hydrophobicity balance of the fluorinated probe for an efficient crossing of the BBB.¹⁷ Finally, the highest achievable sensitivity to ¹⁹F-MRI detection must be pursued by introducing in the molecule as many as possible magnetically equivalent fluorine atoms. A common drawback of fluorinated molecular probes is that their ¹⁹F-NMR linewidth can be significantly affected by binding interactions. If the re-orientational motions of the perfluoroalkyl moieties are restricted in the bound state, a significant line broadening of the ¹⁹F-NMR signal would arise, leading ultimately to a dramatic loss of the ¹⁹F-MRI signal.

Based on these observations, we have designed and synthesized a range of novel curcumin derivatives that contain nine or eighteen equivalent ¹⁹F atoms. To counteract potentially detrimental line-broadening effects, the perfluorinated alkyl groups were linked to the curcumin structure through flexible linkers, such to preserve local re-orientational freedom also in the bound-state. These linkers varied in length and hydrophilicity. Specifically, we have developed three monosubstituted curcumin derivatives, one with a short aliphatic chain (**Curc-C₃-F9**), one with a longer aliphatic chain (**Curc-C₆-F9**), and one with a spacer containing a carboxylic group suitable to improve the solubility (**Curc-Glu-F9**, Fig. 2). The conjugation reactions occur on the hydroxyl groups (4-OH) attached to the phenyl rings of natural product of curcumin. The monosubstituted compounds maintain one curcumin phenolic group, which is known to be important for interaction with fibrils.¹⁸ We also synthesized bis-functionalized derivatives to maximize the number of ¹⁹F atoms per molecule. These probes were assessed for the best compromise between water solubility, fibril targeting ability, and sensitivity to ¹⁹F-MRI detection.




Fig. 1 Structure of curcumin, Shiga-Y5, Shiga Y51, Shiga-Y25.




Fig. 2 Structure of ^{19}F MRI curcumin-based probes synthesized in this work.

Synthesis of the fluorinated curcumin imaging probes


The synthesis of the probes started by preparing the perfluorinated amines, characterized by the presence of the nonafluoro-*tert*-butyloxy tail, using the condensation under Mitsunobu conditions¹⁹ of the readily available 6-(Boc-amino)-1-hexanol or 3-(Boc-amino)-1-propanol with perfluoro-*tert*-butanol (Scheme 1). The corresponding perfluoro-*tert*-butyl ethers were obtained, from which the Boc group was removed in acidic conditions, using a 1:1 mixture of trifluoroacetic acid (TFA) in dichloromethane (CH_2Cl_2). In order to improve the solubility of the final perfluoro curcumin derivative, we also designed a perfluorinated amine containing a carboxylate moiety: thus, compound **F9-C₃-NH₂** with the shorter chain was conjugated to Boc-L-glutamic acid 5-*tert*-butyl ester (Boc-Glu(OtBu)-OH) using DCC/DMAP approach. Then, compound **F9-Glu-NH₂** was obtained as a trifluoroacetate salt after the deprotection of the Boc group with TFA.

While curcumin is naturally derived, its derivatives like those containing ^{19}F in its structure are generally produced by a chemical reaction between by acetylacetone and its derivatives with appropriate aryl-aldehydes. This assembly method can yield multiple chemical analogues, such as compounds with trifluoromethoxy groups on the benzene ring and alkyl substituents on the middle carbon of the linker (C4

position).^{15,20} The functionalization at C4 can be performed by a Michael addition starting from curcumin.²¹ Here, the synthesis of perfluoro curcumin derivatives MRI probes was carried out in four steps starting from commercial *Curcuma longa* powder (C1386, Merck), which is composed of curcumin (77%), demethoxycurcumin (17%), and bisdemethoxycurcumin (3%). Conjugation reactions take place on one or two hydroxyl groups of the phenyl rings of curcumin to synthesize mono- or bifunctional nonafluoro derivatives in a facile synthetic route. The reaction of curcumin with 0.5 equivalents of *t*-butyl bromoacetate in the presence of potassium carbonate as base led to the formation of mono-*t*Bu ester derivative and bis-*t*Bu ester derivative as by-product (compound **1a** and compound **1b**, Scheme 2). The monofunctionalized curcumin was isolated, after purification by column chromatography on silica gel, with about 30% yield. The bis-functionalized derivative was also collected (10% yield) and used for further functionalization to evaluate its binding to the $\text{A}\beta$ aggregates and to compare with the mono-functionalized derivatives. Then, the *t*-Bu esters were deprotected with TFA and the mono and bis-carboxylic acid curcumin derivatives (compound **2a** and **2b**, respectively) were reacted with EDC/NHS in order to obtain the mono and bis-*N*-hydroxysuccinimide esters (Cure-mono-NHS and Cure-bis-NHS, compounds **3a** and **3b**). The final ^{19}F -MRI probes were obtained by amide coupling reaction between the NHS-activated esters of curcumin and the perfluorinated amine (**F9-C₃-NH₂**, **F9-C₆-NH₂** and **F9-Glu-NH₂**) in a mixture of CH_3CN and a phosphate buffer at pH 7.5, at room temperature (Scheme 2). The bis-NHS curcumin **3b** was also conjugated to **F9-C₆-NH₂** and **F9-Glu-NH₂** to afford final bis-perfluorinated derivatives with a higher number of ^{19}F nuclei (**Cure-C₆-F18** and **Cure-Glu-F18**) (Scheme 2). The compounds were then purified by RP-HPLC and characterized by UPLC-UV-MS(ESI $^+$) and NMR spectroscopy. The characteristic ^1H , ^{19}F , 2D ^1H , ^1H -COSY, 2D ^1H , ^{13}C -HSQC, 2D ^1H , ^{13}C -HMBC NMR (600 MHz, DMSO-d₆, 300 K) and ^{19}F NMR (500 MHz, ethanol, 300 K) of all ^{19}F -curcumin imaging probes reported are presented as ESI, † as well as the UPLC-UV-MS(ESI $^+$) chromatogram. The complete ^1H NMR chemical shift assignment of **Cure-C₃-F9** dissolved in DMSO-d₆ is shown in Fig. 3. The peak at 6.13 ppm corresponds to the proton on the α -carbon in the keto-enol tautomer (H1 in Fig. 3). Moreover, the methoxy, the aromatic and the conjugated methyne protons of the two sides of the molecule are not magnetically equivalent confirming the asymmetry of the structure. For all compounds, the purity was found to be between 96 and 98% as measured by UPLC at $\lambda = 220$ nm and $\lambda = 413$ nm.


Binding activity of curcumin derivatives to the amyloid-beta ($\text{A}\beta$) fibrils

$\text{A}\beta$ aggregates in protofibrillar and fibrillar state were prepared by incubating $\text{A}\beta$ 1–42 peptide (50 μM) in phosphate buffer 10 mM (pH 7.4) containing 11 mM NaCl, for 4 days at 37 °C under stirring.²² The formation of $\text{A}\beta$ aggregates was checked by measuring Thioflavin-T (ThT) fluorescence enhancement during fibril formation at 37 °C under stirring at 600 rpm (see



Scheme 1 Synthesis of perfluoroamine derivatives: (i) nonafluoro-*tert*-butyl alcohol, PPh_3 , DIAD, Et_2O , (ii) TFA, CH_2Cl_2 , (iii) Boc-Glu(OtBu)-OH, DCC, DMAP, CH_2Cl_2 , (iv) TFA, CH_2Cl_2 (1:1).





Scheme 2 Synthesis of mono and bis-perfluorinated curcumin derivatives: (i) *t*-butyl bromoacetate, K_2CO_3 in CH_3CN ; (ii) TFA/ CH_2Cl_2 (1 : 1); (iii) EDC/NHS, 5 mol% DMAP in NMP; (iv) $F_9-C_3-NH_2$ or $F_9-C_6-NH_2$ or $F_9-Glu-NH_2$, buffer phosphate (0.1 M, pH = 7.5), CH_3CN .




Fig. 3 1H -NMR spectrum of compound Curc-C3-F9 ($DMSO-d_6$, 300 K).

Fig. 4A). ThT exhibits a significant shift in the excitation maximum (from 385 nm to 450 nm) and the emission maximum (from 445 nm to 482 nm) due to its binding to $A\beta$.²³ ThT is an effective indicator of fibrilization, as confirmed by morphological analysis using field emission scanning electron microscopy (FESEM) (Fig. 4B). These experiments showed that

aggregation and maturity of the fibrils was optimal after 5 days incubation under our experimental conditions.

Curcumin and its fluorinated derivatives, at the concentrations used, generate negligible fluorescence emission in the range 488–497 nm. In the absence of fibrils (Fig. 5, dashed line, $\lambda_{ex} = 450$ nm). The binding of curcumin and its




Fig. 4 (A) ThT fluorescence enhancement at different times of incubation (37 °C, under stirring, [A_β] 300 nM, [ThT] 50 nM, ex. 450 nm, em. 476 nm). (B) FESEM images of A_β aggregates (5 days incubation) at 15kx and 100kx magnification, probe set at 100 pA and the electron beam energy at 5 keV.




Fig. 5 Fluorescence emission spectra ($\lambda_{\text{ex}} = 450$ nm) as a function of aggregated A_β: (A) Curc-C₃-F9, 22.0 nM; (B) Curc-C₆-F9, 25.6 nM; (C) Curc-Glu-F9, 20.8 nM; (D) Curc-Glu-F18, 28.3 nM; (E) Curc-C₆-F18, 25.0 nM; (F) curcumin, 21.0 nM.

derivatives to mature A_β fibrils is known to be characterised by a steep increase of their fluorescence emission^{24a,b} and also by a red shift of the absorption maximum.^{25a,b} In our conditions, the maximum fluorescence emission of curcumin derivatives in the presence of A_β fibrils was found using an excitation wavelength of 450 nm. This excitation wavelength was used in binding titrations, where a fixed amount of a curcumin derivative was incubated with increasing amounts of A_β fibrils. The fluorescence emission at around 490 nm was plotted as a function of the fibril concentration to obtain binding isotherms (Fig. 6), from which the binding affinity K_a for A_β could be extracted by computer aided best fitting to eqn (1) (Experimental section). The obtained thermodynamic association constants K_a , assuming a 1:1 interaction with A_β, are listed in Table 1.

The affinity constant K_a for curcumin obtained by this assay is in line with that reported in the literature.²⁶ All fluorinated compounds showed a good affinity for fibrils, with K_a in the range ($1.1\text{--}3.9 \times 10^5 \text{ M}^{-1}$), except Cur-C₆-F18. The latter compound showed a very low fluorescence increase which prevented the calculation of its affinity constant. This could be likely due to the very poor solubility of the compound in aqueous medium (see below).

While the extension of the spacer between curcumin and the perfluoro-*tert*-butyl ether from C₃ to C₆ does not affect the affinity, the presence of a carboxylic group, which is negatively charged at neutral pH, slightly reduces the K_a of **Cure-Glu-F9** derivative.

Although it is known that at least one phenolic group in the aromatic portion of the structure is needed to preserve binding to the fibril beta-sheets layer, we found that the disubstituted **Cure-Glu-F18** (having no such phenolic group) had a binding affinity in the same order of magnitude of the mono-substituted **Cure-Glu-F9** counterpart. We might speculate that the two amide groups within each of the linkers of **Cure-Glu**




Fig. 6 Plot of the fluorescence emission ($\lambda_{\text{ex}} = 450$ nm) of curcumin and its derivatives: (A) Curc-C₃-F9, $\lambda_{\text{em}} = 497$ nm, $R^2 = 0.99957$; (B) Curc-C₆-F9, $\lambda_{\text{em}} = 495$ nm, $R^2 = 0.99836$; (C) Curc-Glu-F9, $\lambda_{\text{ex}} = 495$ nm, $R^2 = 0.99334$; (D) Curc-Glu-F18, $\lambda_{\text{em}} = 488$ nm, $R^2 = 0.992$; (E) Curc-C₆-F18, $\lambda_{\text{ex}} = 488$ nm; (F) curcumin, $\lambda_{\text{em}} = 495$ nm, $R^2 = 0.91$. Titrations were done in triplicate. Error bars correspond to $\pm \text{SD}$ of the mean values.



Table 1 Molar fluorescence intensities of the $\text{A}\beta$ bound compounds (F_b) and association constants (K_a)

Sample	$F_b \pm \text{SD (CPS mA}^{-1} \text{M}^{-1}\text{)}$	$K_a \pm \text{SD (M}^{-1}\text{)}$
Cure-C₃-F9	$5.5 \times 10^{13} \pm 1.1 \times 10^{13}$	$3.8 \times 10^5 \pm 0.9 \times 10^5$
Cure-C₆-F9	$3.2 \times 10^{13} \pm 3.2 \times 10^{13}$	$3.9 \times 10^5 \pm 0.8 \times 10^5$
Cure-Glu-F9	$1.7 \times 10^{14} \pm 0.4 \times 10^{14}$	$1.1 \times 10^5 \pm 0.9 \times 10^5$
Cure-Glu-F18	$3.5 \times 10^{13} \pm 2.9 \times 10^{13}$	$2.1 \times 10^5 \pm 0.2 \times 10^5$
Cure-C₆-F18	n.d.	n.d.
Curcumin	$9.7 \times 10^{14} \pm 7.4 \times 10^{14}$	$2.6 \times 10^5 \pm 1.3 \times 10^5$

F18 may provide suitable hydrogen bonding capabilities to form a suitable hydrogen bond network with the fibril.

Binding to human serum albumin (HSA)

For an initial assessment of the binding selectivity, we chose serum albumin as a model protein offering multiple potential binding sites for the fluorinated compounds, each site having different binding properties. It has been reported that the curcumin fluorescence emission in the 450–490 nm range (with λ_{ex} at 430 nm) strongly increases when bound to the hydrophobic pockets of HSA.²⁶ To this purpose the fluorescence emission at 485 nm was plotted as a function of the HSA concentration, assuming a 1 : 1 interaction (see ESI, section 3†). As expected, reference curcumin showed specific binding to HSA with an affinity constant K_a of $5.9 \times 10^5 \text{ M}^{-1}$, in line with the value reported in the literature.²⁷ The monosubstituted **Cure-C₆-F9** and **Cure-Glu-F9** showed a very low binding to HSA as demonstrated by the low fluorescence increase compared to the autofluorescence of HSA alone at the same concentrations. The only compound showing a binding affinity for HSA was **Cure-Glu-F18**, with a binding affinity constant higher than that of reference curcumin ($K_a = 4.2 \times 10^6 \text{ M}^{-1}$).

Solubility of fluorinated curcumin derivatives

All fluorinated curcumin derivatives exhibit pronounced hydrophobicity, especially the bis-functionalized **Cure-C₆-F18** derivative, which does not dissolve in any of the potentially injectable formulations prepared for *in vivo* use. The very low solubility in aqueous medium is due to the presence of the central curcuminoid body, consisting of a conjugated alkenyl and aromatic components, as well as the transformation of the curcumin -OH groups into alkyl ethers terminating with three bulky and hydrophobic -CF₃ groups. To achieve a suitable solubility and stability of the solutions in water, addition of CREMOPHOR EL, a non-ionic surfactant derived from castor oil, was necessary. The solubility properties of the compounds at 10 mg mL⁻¹ in DMSO, MeOH, and HEPES buffer with the addition of 10% and 20% CREMOPHOR are shown in Table 2. The curcumin derivatives that gain a negative charge at physiological pH (**Cure-Glu-F9** and **Cure-Glu-F18**) have been shown to effectively enhance water solubility.

¹⁹F-NMR study

Compounds **Cure-C₆-F9**, **Cure-Glu-F9**, and **Cure-Glu-F18**, which showed an acceptable solubility in the hepes/cremophor bio-

Table 2 Solubility of the synthesized compounds in DMSO, methanol and HEPES + cremophor^a at 10 mg mL⁻¹

Sample	DMSO	MEOH	HEPES + cremophor 10%	HEPES + cremophor 20%
Cure-C₆-F9	+	+	—	+
Cure-C₆-F18	+	+	—	—
Cure-Glu-F9	+	+	+	+
Cure-Glu-F18	+	+	+	+

^a The LD₅₀ of cremophor surfactant was verified in the literature²⁸ and a significantly smaller amount was used in the tests.

compatible medium, were selected for ¹⁹F-MRI sensitivity assessment. All these compounds show a single ¹⁹F-NMR singlet falling 4–5 ppm upfield relative to TFA (see ESI section 2.14†). In MRI signal acquisition, the relaxation times T_1 and T_2 of ¹⁹F nuclei play a crucial role, as they determine both the signal-to-noise ratio achievable in the image and the acquisition times of the imaging experiment. Indeed, high values of T_1 (greater than 1 s) require long acquisition times, while too small values of T_2 (less than 100 ms) result in signal loss due to both line-broadening and dead times of the acquisition sequence. The T_1 and T_2 values for the single ¹⁹F resonance of the synthesized products are reported in Table 3.

The relaxation times are within the suitable range for ¹⁹F-MRI. Indeed, T_1 values around 500 ms allow for the acquisition of a reasonable number of images in a short time without saturating the signal, while T_2 values slightly above 100 ms are enough to avoid appreciable signal loss during spin-echo trains. Accordingly, ¹⁹F MR-images show a good signal-to-noise and the expected proportionality of the ¹⁹F-MRI signal intensity to the number of fluorine atoms present in each compound (Table 3 and Fig. 7).

Next, we tried to acquire the ¹⁹F-NMR signal in the presence of amyloid fibrils. The critical issue in this kind of measurement is that our model of amyloid fibrils is incompatible with the surfactant needed to solubilize the probe. Therefore, experiments were carried out without the surfactant with compound **Cure-Glu-F9**, which showed the best compromise between binding affinity to fibrils, selectivity and water solubility. In phosphate buffer (without any surfactants) **Cure-Glu-F9** (50 μM) yielded a barely detectable signal (Fig. 8A), because the compound aggregates into supramolecular structures having a heterogeneous distribution of molecular sizes and leading to a substantial line-broadening. In the presence of monomers or oligomers at 50 μM concentration, a ¹⁹F-NMR

Table 3 ¹⁹F-NMR relaxation times and ¹⁹F-MRI signal-to-noise ratio (SNR) in phantoms (at 7 T and 25 °C) of fluorinated curcumin derivatives at a concentration of 4.5 mM

	T_1 (ms)	T_2 (ms)	SNR
Cure-C₆-F9 HEPES + cremophor 20%	610	126	13.7
Cure-Glu-F9 HEPES + cremophor 10%	558	139	11.4
Cure-Glu-F18 HEPES + cremophor 10%	523	102	22.0






Fig. 7 ^1H , ^{19}F , and merged MRI of (a) Curc-C₆-F9, (b) Curc-Glu-F9, (c) and Curc-Glu-F18 solubilized at 4.5 mM in HEPES/NaCl buffer + cremophor. The normalized ^{19}F signal intensity scale is reported in the calibration bar. The central cone is to provide an appropriate volume for shimming.




Fig. 8 ^{19}F -NMR spectrum of Curc-Glu-F9: (A) without A β , (B) with A β monomers, (C) with soluble A β oligomers and (D) with mature fibrils. Asterisks denote TFA (*) and hexafluoro-2-propanol (HFIP, **) as contaminants.

signal at -70.6 ppm (linewidth about 25 Hz) became clearly detectable (Fig. 8B and C). In such experimental conditions, the theoretically expected fraction of fibril-bound probe would be 80%. In the presence of mature fibrils, the signal disappears (Fig. 8D). The increase of ^{19}F -NMR signal intensity in the presence of monomers/oligomers is explained in terms of the establishment of a binding equilibrium between the aggregated, NMR invisible form of the fluorinated compound and an NMR detectable form where **Curc-Glu-F9** is bound to amyloid monomers/oligomers.

In the presence of mature fibrils, such adducts have a large molecular size, leading to massive ^{19}F -NMR line broadening which in turn hampers the detection of the ^{19}F -NMR signal. These results indicate that, under the *in vitro* assay conditions, **Curc-Glu-F9** can detect A β monomers/oligomers rather than mature fibrils. Soluble A β oligomers are toxic to neurons and are believed to be major contributors to synaptic dysfunction and neuronal death observed in Alzheimer's disease. Detection and quantification of soluble A β and tau oligomers in cerebrospinal fluid (CSF) may serve as pre-symptomatic biomarkers.^{29a,b} This approach to study the binding interaction has limitations, as the *in vitro* conditions may not

mimic properly those likely met in a physiological environment. For instance, fibril-bound forms may exist in equilibrium with forms bound to the hydrophobic components of the ECM rather than in equilibrium with self-aggregated forms. *In vivo* studies with murine models of brain deposition of amyloid fibrils are awaited to gain further insights about the NMR properties of the ^{19}F -NMR signal, and to assess whether the high number of fluorine atoms is paralleled by a proportional increase of signal intensity. As a matter of fact, such kind of studies for the compounds of the Shiga-family were carried out directly by *in vivo* measurements.^{12,14,16}

Conclusions

The use of ^{19}F -MRI to detect amyloid fibrils in the brain presents several challenges. The main hurdle is the limited sensitivity of the ^{19}F -MRI technique, eventually requiring a high concentration of fluorine-19 nuclei in the imaging voxel (in the order of millimoles per litre), under a realistic clinical scenario,³⁰ and a suitably small signal linewidth. We successfully synthesized new curcumin derivatives substituted with one or two perfluoro-*tert*-butyl groups, containing 9 or 18 equivalent fluorine atoms respectively. Amongst these compounds, the monosubstituted **Curc-Glu-F9** (i) retained a high binding affinity towards A β fibrils; (ii) had an acceptable water solubility in formulation with surfactants; and (iii) showed a detectable ^{19}F -NMR signal in the form bound to A β oligomers in a preliminary *in vitro* assay. *In vivo* studies are needed to determine if the large number of equivalent fluorine atoms per molecule will result in a corresponding increase in ^{19}F -MRI signal intensity in a more realistic brain imaging setting.

Experimental

General synthetic methods

All reagents were purchased by Sigma Aldrich (Darmstadt, Germany) and solvents by VWR International (Radnor, USA) and were used without further purifications. Column chromatographic separations were performed using silica gel (VWR International) with a particle size of 0.040–0.063 mm. Preparative HPLC-MS were carried out on a Waters AutoPurification system (3100 Mass Detector, 2545 Pump Gradient Module, 2767 Sample Manager, and 2998 PDA detector). UPLC analysis was performed using a UPLC Acquity H-Class coupled with the QDa and TUV detectors, using Kinetex® F5 column, 1.7 μm , 2.1 \times 100 mm, applying a gradient of CH₃CN (0.05% TFA) in H₂O (0.05% TFA) from 50% to 100% in 8 min and 100% of B in 4 min (0.2 mL min⁻¹), peak area revealed at 210 nm and 430 nm (method 1). All compounds are >95% pure by HPLC. NMR spectra were recorded at 310 K on a Bruker AVANCE 600 MHz and a Bruker Avance Neo 500 MHz spectrometer.



Synthesis of mono-NHS and bis-NHS esters of curcumin

Synthesis of 1a and 1b. 1.0 g of curcumin (2.7 mmol) was dissolved in 100 mL of acetonitrile and 0.2 g (1.4 mmol) of sodium sulfate and 0.7 g (5 mmol) of potassium carbonate were added to the solution. Then, 0.2 mL (1.3 mmol) of *t*-butyl bromoacetate in 5 mL CH₃CN were added slowly dropwise to the mixture which was stirred under reflux and argon atmosphere for 2 h. The reaction was cooled to room temperature, all salts were filtered and the solvent was evaporated. The crude product was purified by flash chromatography (silica gel column, petroleum ether/ethyl acetate 8 : 2 to 1 : 1) to give **1a** (0.34 g, yield 30%) and **1b** (0.53 g, yield 19%) as a yellow oil. Compound **1a**: ¹H NMR (DMSO-d₆), δ (ppm): 9.70 (s, 1H, phenolic-OH), 7.60 (d, 2H, J = 15.8 Hz, H4/H4'), 7.41 (s, 1H, H6), 7.41 (s, 1H, H6'), 7.27 (d, 1H, J = 8.0 Hz, H10), 7.20 (d, 1H, J = 8.2 Hz, H10'), 6.93 (d, 1H, J = 8.3 Hz, H9), 6.88 (d, 1H, J = 15.8 Hz, H3), 6.86 (d, 1H, J = 8.3 Hz, H9'), 6.80 (d, 1H, J = 15.9 Hz, H3'), 6.13 (s, 1H, H1), 4.76 (s, 2H, H12), 3.89 (s, 3H, H20), 3.88 (s, 3H, H20'), 1.47 (s, 9H, *t*Bu) (see ESI section 2.1†). Direct infusion mass analysis with methanol/water 9 : 1 v:v at 0.2 mg mL⁻¹: ESI-MS (*m/z*): calcd: for C₂₇H₃₀O₈ [M + H]⁺ 483.19 found: 483.35. Compound **1b**: ¹H NMR (DMSO-d₆), δ (ppm): 7.61 (d, 2H, J = 15.9 Hz, H4/H4'), 7.30 (s, 2H, H6/H6'), 7.27 (d, 2H, J = 8.4 Hz, H10/H10'), 6.94 (d, 2H, J = 8.4 Hz, H9, H9'), 6.87 (d, 2H, J = 15.9 Hz, H3/H3'), 6.16 (s, 1H, H1), 4.72 (s, 4H, H12/H12'), 3.88 (s, 6H, H20/H20'), 1.46 (s, 18H, *t*Bu). Direct infusion mass analysis with methanol/water 9 : 1 v:v at 0.2 mg mL⁻¹: ESI-MS (*m/z*): calcd: for C₃₃H₄₀O₁₀ [M + H]⁺ 597.26 found: 597.37.

Synthesis of 2a and 2b. 10 mL of TFA were added at room temperature to a solution of 0.28 g (0.58 mmol) of **1a** in 3 mL CH₂Cl₂. After 4 h, the solution was concentrated *in vacuo* and the product was precipitated adding Et₂O (20 mL); the resulting yellow solid was centrifuged (6000 rpm, 30 min) and then washed with Et₂O (20 mL × 3), collected and dried *in vacuo* to give **2a** (0.22 g, yield 88%) as a yellow powder. Compound **2b** was obtained by performing the same procedure starting from 0.3 g (0.5 mmol) of **1b** (0.37 g, yield 84%).

Compound **2a**: UPLC-UV (λ = 220 nm, 430 nm): *t*_R 2.05 min, 98% purity. ¹H-NMR (DMSO-d₆), δ (ppm): 16.33 (exch br s, 1H, H11), 13.06 (exch br s, 1H, COOH), 9.67 (s, 1H, phenolic-OH), 7.60 (d, 2H, J = 15.9 Hz, H4/H4'), 7.41 (s, 1H, H6), 7.36 (s, 1H, H6'), 7.26 (d, 1H, J = 8.1 Hz, H10), 7.20 (d, 1H, J = 8.3 Hz, H10'), 6.94 (d, 1H, J = 8.1 Hz, H9), 6.87 (d, 1H, J = 15.9 Hz, H3), 6.86 (d, 1H, J = 8.3 Hz, H9'), 6.80 (d, 1H, J = 15.9 Hz, H3'), 6.13 (s, 1H, H1), 4.78 (s, 2H, H12), 3.88 (s, 3H, H20), 3.87 (s, 3H, H20'). ¹³C NMR (DMSO-d₆), δ (ppm): 184.4, 183.2, 170.5, 150.0, 149.8, 149.7, 148.6, 141.6, 140.7, 128.8, 126.9, 123.8, 123.0, 122.9, 121.7, 116.3, 113.5, 112.0, 111.6, 101.5, 65.5, 56.3. ESI-MS (*m/z*): calcd: for C₂₃H₂₂O₈ [M + H]⁺ 427.13 found: 427.33; [M + Na]⁺ 449.12 found: 449.34 (see ESI section 2.2†).

Compound **2b**: UPLC-UV (λ = 220 nm, 254 nm): *t*_R 2.50 min, 93% purity.¹ ¹H NMR (DMSO-d₆), δ (ppm): 7.62 (d, 2H, J = 15.9 Hz, H4/H4'), 7.41 (s, 2H, H6/H6'), 7.27 (d, 2H, J = 8.4 Hz, H10/H10'), 6.94 (d, 2H, J = 8.4 Hz, H9, H9'), 6.88 (d, 2H, J = 15.9 Hz,

H3/H3'), 6.16 (s, 1H, H1), 4.77 (s, 4H, H12/H12'), 3.88 (s, 6H, H20/H20'). ¹³C NMR (DMSO), δ (ppm): 184.9, 172.6, 151.5, 151.2, 141.8, 131.2, 123.9, 123.8, 115.4, 112.5, 67.0, 56.8. ESI-MS (*m/z*): calcd: For C₂₅H₂₄O₁₀ [M + H]⁺ 485.14 found: 485.26 (see ESI section 2.3†).

Synthesis of 3a and 3b. 0.36 g of **2a** (0.84 mmol) were dissolved in 1 mL of *N*-methyl pyrrolidone (NMP). EDC (0.24 g, 1.26 mmol), NHS (0.14 g, 1.26 mmol) and 5 mol% DMAP were added to the solution. The reaction mixture was stirred for 2 h at room temperature. The product was precipitated adding Et₂O (30 mL), the resulting yellow solid was centrifuged (6000 rpm, 30 min) and washed with Et₂O (20 mL × 3) and EtOAc (20 mL × 3) and then collected and dried. For compound **2b**: 3 equivalents of EDC and NHS were used starting from 0.2 g (0.4 mmol) of compound **2b**. The products were used directly for the next step without further purification. Direct infusion mass analysis with methanol/water 9 : 1 v:v at 0.2 mg mL⁻¹: Compound **3a**: ESI-MS (*m/z*): calcd: for C₂₇H₂₅NO₁₀ [M + H]⁺ 524.15 found: 524.26; [M + Na]⁺ 546.49; Compound **3b**: ESI-MS (*m/z*): calcd: for C₃₃H₃₀N₂O₁₄ [M + H]⁺ 679.17 found: 679.37; [M + Na]⁺ 701.61.

Synthesis of F9-C₃-NH₂ and F9-C₆-NH₂

3-(Boc-amino)-1-propanol (0.37 g, 2.1 mmol) or 6-(Boc-amino)-1-hexanol (0.46 g, 2.1 mmol) and triphenylphosphine (0.66 g, 2.52 mmol) in Et₂O (16 mL) were added to an ice cooled and stirred solution of nonafluoro-*tert*-butyl alcohol (0.5 g, 2.1 mmol) in Et₂O (8 mL). After 5 min, a solution of diisopropyl azodicarboxylate (DIAD, 0.55 g, 2.73 mmol) in Et₂O (5 mL) was added during 15 min. Then, the ice bath was removed and the mixture stirred at RT for 24 h. The solid precipitate was removed by filtration and the filtrate evaporated. The crude product was purified by chromatography (silica gel column, DCM/MeOH 98 : 2) to afford Boc-HN-C₃-F9 or Boc-HN-C₆-F9 as a yellow oil (52% and 32%, respectively). For the deprotection of the Boc-group, 0.3 g of Boc-perfluoroamine were dissolved in CH₂Cl₂ (2 mL) and cooled to 0 °C. 2 mL of TFA were added and the solution was allowed to warm to room temperature. After stirring at room temperature until starting material was consumed (TLC monitoring) the solution was concentrated *in vacuo* (ca. 80%). Boc-NH-C₃-F9: ¹H-NMR (CDCl₃, 600 MHz) δ 1.48 (s, 9H), 1.94 (t, 2H, J = 5.92), 3.29 (m, 2H), 4.13 (t, 2H, J = 5.96). ESI-MS (*m/z*): calcd: for C₁₂H₁₆F₉NO₃ [M + H]⁺ 394.10 found: 394.14. **F9-C₃-NH₂**: ¹H-NMR (MeOD, 600 MHz) δ 2.12 (m, 2H), 3.10 (m, 2H), 4.28 (t, 2H, J = 5.93), 6.87 (m, 3H) (see ESI section 2.4†). ESI-MS (*m/z*): calcd: for C₇H₈F₉NO [M + H]⁺ 294.05 found: 294.13. Boc-NH-C₆-F9: ¹H-NMR (CDCl₃, 600 MHz) δ 1.39 (m, 2H), 1.46 (m, 2H), 1.50 (s, 9H), 1.54 (m, 2H), 1.73 (m, 2H), 3.16 (t, 2H), 4.05 (t, 2H). ¹³C-NMR (CDCl₃, 600 MHz) δ 24.32, 25.60, 27.67, 28.88, 29.22, 39.71, 68.99, 116.76, 118.72, 120.66, 122.58, 155.26. ESI-MS (*m/z*): calcd: for C₁₅H₂₂F₉NO₃ [M + H]⁺ 436.15 found: 436.15. **F9-C₆-NH₂**: ¹H-NMR (MeOD 600 MHz) δ 1.51 (m, 4H), 1.71 (m, 2H), 1.79 (m, 2H), 2.97 (m, 2H), 4.15 (t, 2H, J = 5.94) (see ESI section 2.5†). ¹³C-NMR (MeOD, 600 MHz) δ 23.91, 24.92, 26.30, 28.43,



38.50, 69.17, 116.80, 118.72, 120.67, 122.62, 159.03. ESI-MS (*m/z*): calcd: for $C_{10}H_{14}F_9NO$ [M + H]⁺ 336.09 found: 336.27.

Synthesis of F9-Glu-NH₂

Boc-L-glutamic acid 5-*tert*-butyl ester (0.18 g, 0.6 mmol) was dissolved in 10 mL of CH₃CN and DIPEA (0.18 g, 1.4 mmol) and HATU (0.23 g, 0.7 mmol) were added. After 5 min, **F9-C₃-NH₂** (0.2 g, 0.7 mmol) dissolved in CH₃CN (1 mL) was added dropwise and then the mixture was stirred at room temperature for 6 h under N₂ atmosphere. The solvent was then removed under vacuum and the residue was dissolved in CH₂Cl₂ (10 mL) and washed three times with brine (2 × 10 mL) and water (2 × 10 mL) and the separated organic phases were dried with anhydrous Na₂SO₄. Then, the crude product obtained by evaporation of the solvent was purified by chromatography (silica gel column, petroleum ether/ethyl acetate 7 : 3) to give F9-C₃-Glu(OtBu)-NH-Boc as a pale yellow oil (55%). ¹H-NMR (CDCl₃, 600 MHz) δ 1.49 (s, 9H), 1.51 (s, 9H), 1.88 (m, 1H), 1.98 (m, 2H), 2.19 (m, 1H), 2.30 (m, 2H), 3.43 (m, 2H), 4.16 (m, 3H), 5.31 (s, 1H), 6.63 (s, 1H). ¹³C-NMR (CDCl₃, 600 MHz) δ 27.16, 27.56, 28.85, 29.21, 31.85, 35.78, 52.64, 67.62, 79.05, 81.67, 116.33, 118.58, 120.64, 122.51, 155.43, 170.70, 171.73. ESI-MS (*m/z*): calcd: for $C_{21}H_{31}F_9N_2O_6$ [M + H]⁺ 579.20 found: 579.36. For the deprotection of the Boc and *tert*-butyl groups, 0.2 g of F9-C₃-Glu(OtBu)-NH-Boc were dissolved in CH₂Cl₂ (2 mL) and cooled to 0 °C; then, 2 mL of TFA were added and the solution was allowed to warm to room temperature. After stirring at room temperature overnight the solution was concentrated *in vacuo* to obtain F9-C₃-Glu-NH₂ in 92% yield. ¹H-NMR (DMSO-d₆, 600 MHz) δ 1.85 (m, 2H), 2.02 (m, 2H), 2.32 (m, 2H), 3.18 (m, 2H), 3.97 (m, 1H), 4.13 (t, 2H, *J* = 6.41 Hz), 8.03 (t, 1H, *J* = 5.33 Hz), 8.27 (s, 2H) (see ESI section 2.6†). ¹³C-NMR (CDCl₃, 600 MHz) δ 28.05, 30.36, 32.86, 36.58, 54.74, 64.52, 116.24, 118.42, 172.40, 174.83. ESI-MS (*m/z*): calcd: for $C_{12}H_{15}F_9N_2O_4$ [M + H]⁺ 423.09 found: 423.18.

Synthesis of monosubstituted curcumin derivatives (Cure-C₃-F9, Cure-C₆-F9, Cure-Glu-F9)

A solution of mono-NHS ester of curcumin (compound **3a**, 0.38 mmol) in acetonitrile (4 mL) was slowly added at room temperature to a solution of perfluoroamine (**F9-C₃-NH₂**, **F9-C₆-NH₂**, **F9-Glu-NH₂**) (0.38 mmol) dissolved in sodium phosphate buffer (0.1 M, pH 7.5, 4 mL) and CH₃CN (4 mL). The biphasic mixture was allowed to stir vigorously for 2 h. Then the acetonitrile was evaporated under reduced pressure and the aqueous phase was washed with dichloromethane (3 × 100 mL). The organic phase was dried with anhydrous Na₂SO₄, and, after filtration, the solvent was evaporated to give yellow solids. The solids were then purified by preparative HPLC by using a Water XterraTM Prep RPdC8 19/100 column, applying a gradient of CH₃CN (0.1% TFA) in H₂O (0.1% TFA) from 50% to 100% in 15 min (20 mL min⁻¹). The pure products were obtained as yellow powders. The purity of the compounds was determined by UPLC using method 1.

Cure-C₃-F9: (0.17 g). Yield: 62%, *t_R* 5.80 min, 98% purity. ¹H-NMR (600 MHz, DMSO-d₆, 300 K), δ ppm: 9.69 (s, 1H, phe-

nolic-OH), 8.08 (t, *J* = 5.6 Hz, 1H, H14), 7.61 (d, *J* = 15.9 Hz, 2H, overlapping H4/H4'), 7.43 (d, *J* = 1.9 Hz, 1H, H6), 7.37 (d, *J* = 1.9 Hz, 1H, H6'), 7.27 (dd, *J* = 8.3 and 1.9 Hz, 1H, H10), 7.20 (dd, *J* = 8.2 and 1.9 Hz, 1H, H10'), 6.97 (d, *J* = 8.3 Hz, 1H, H9), 6.88 (d, 15.9 Hz, 1H, H3), 6.87 (d, *J* = 8.2 Hz, 1H, H9'), 6.81 (d, *J* = 15.9 Hz, 1H, H3'), 6.13 (s, 1H, H1), 4.57 (s, 2H, H12), 4.13 (t, *J* = 6.2 Hz, 2H, H17), 3.90 (s, 3H, H20), 3.88 (s, 3H, H20'), 3.27 (q, *J* = 6.2 Hz, 2H, H15), 1.88 (m, *J* = 6.2 Hz, 2H, H16) (see ESI section 2.7† for details and NMR assignment). ¹⁹F-NMR (470 MHz, ethanol/DMSO-d₆ 550 : 50, 298 K), δ ppm (relative to TFA -76.55 ppm): -71.71 (s). ¹³C-NMR (150 MHz, δ ppm from 2D HSQC and 2D HMBC, DMSO-d₆, 300 K): 184.4 (C2'), 182.8 (C2), 168.0 (C13), 150.0 (overlapping C7, C8, C8'), 148.5 (C7'), 141.4 (C4'), 140.3 (C4), 129.2 (C5), 126.7 (C5'), 123.7 (C10'), 123.0 (C3), 122.7 (C10), 121.6 (C3'), 116.3 (C9'), 114.3 (C9), 111.8 (C6'), 111.5 (C6), 101.3 (C1), 68.8 (C17), 68.6 (C12), 56.2 (overlapping C20, C20'), 35.2 (C15), 29.8 (C16). ESI-MS (*m/z*): calcd: for $C_{30}H_{28}F_9NO_8$ [M + H]⁺ 702.17 found: 702.19; [M + Na]⁺ 724.33.

Cure-C₆-F9: (0.15 g). Yield: 52%, *t_R* 6.58 min, 98% purity. ¹H-NMR (600 MHz, DMSO-d₆, 300 K), δ ppm: 9.70 (s, 1H, phenolic-OH), 7.95 (t, *J* = 5.7 Hz, 1H, H14), 7.60 (d, *J* = 15.8 Hz, 2H, overlapping H4/H4'), 7.43 (d, *J* = 1.9 Hz, 1H, H6), 7.36 (d, *J* = 1.9 Hz, 1H, H6'), 7.27 (dd, *J* = 8.4 and 1.9 Hz, 1H, H10), 7.20 (dd, *J* = 8.4 and 1.9 Hz, 1H, H10'), 6.97 (d, *J* = 8.4 Hz, 1H, H9), 6.88 (d, *J* = 15.8 Hz, 1H, H3), 6.86 (d, *J* = 8.4 Hz, 1H, H9'), 6.80 (d, *J* = 15.8 Hz, 1H, H3'), 6.12 (s, 1H, H1), 4.56 (s, 2H, H12), 4.09 (t, *J* = 6.2 Hz, 2H, H20), 3.90 (s, 3H, H23), 3.88 (s, 3H, H23'), 3.15 (q, *J* = 6.2 Hz, 2H, H15), 1.66 (m, *J* = 6.4 Hz, 2H, H19), 1.46 (m, *J* = 7.4 Hz, 2H, H16), 1.37 (m, *J* = 7.4 Hz, 2H, H18), 1.295 (m, *J* = 7.4 Hz, 2H, H17) (see ESI section 2.8† for details and NMR assignment). ¹⁹F-NMR (470 MHz, ethanol/DMSO-d₆ 550 : 50, 298 K), δ ppm (relative to TFA -76.55 ppm): -71.79 (s). ¹³C-NMR (150 MHz, δ ppm from 2D HSQC and 2D HMBC, DMSO-d₆, 300 K): 184.4 (C2'), 182.7 (C2), 167.7 (C13), 149.8 (overlapping C7, C8, C8'), 148.7 (C7'), 141.5 (C4'), 140.2 (C4), 129.2 (C5), 126.7 (C5'), 123.7 (C10'), 123.0 (C3), 122.9 (C10), 121.6 (C3'), 116.2 (C9'), 114.4 (C9), 111.8 (C6'), 111.5 (C6), 101.4 (C1), 70.7 (C20), 68.5 (C12), 56.15 (overlapping C23, C23'), 38.6 (C15), 29.55 (C19), 29.3 (C16), 26.3 (C17), 24.9 (C16). ESI-MS (*m/z*): calcd: for $C_{33}H_{34}F_9NO_8$ [M + H]⁺ 744.21 found: 744.28; [M + Na]⁺ 766.25.

Cure-Glu-F9: (0.08 g). Yield: 34%, *t_R* 4.13 min, 97% purity. ¹H-NMR (600 MHz, DMSO-d₆, 300 K), δ ppm: 9.70 (s, 1H, phenolic-OH), 8.24 (br, 1H, H14), 7.92 (t, *J* = 5.6 Hz, 1H, H19), 7.60 (d, *J* = 15.8 Hz, 2H, overlapping H4/H4'), 7.43 (d, *J* = 1.6 Hz, 1H, H6), 7.36 (d, *J* = 1.6 Hz, 1H, H6'), 7.26 (dd, *J* = 8.4 and 1.6 Hz, 1H, H10), 7.20 (dd, *J* = 8.4 and 1.6 Hz, 1H, H10'), 7.01 (d, *J* = 8.3 Hz, 1H, H9), 6.88 (d, *J* = 15.8 Hz, 1H, H3), 6.86 (d, *J* = 8.4 Hz, 1H, H9'), 6.80 (d, *J* = 15.8 Hz, 1H, H3'), 6.13 (s, 1H, H1), 4.64 (AB system, 2H, H12), 4.28 (m, br, 1H, H15), 4.11 (t, *J* = 6.2 Hz, 2H, H22), 3.90 (s, 3H, H26), 3.88 (s, 3H, H26'), 3.15 (q, *J* = 6.6 Hz, 2H, H20), 2.16 (m, 2H, H17), 2.06 (m, 1H, H16a), 1.87 (m, 1H, H16b), 1.81 (m, *J* = 6.5 Hz, 2H, H21) (see ESI section 2.9† for details and NMR assignment). ¹⁹F-NMR (470 MHz, ethanol/DMSO-d₆ 550 : 50, 298 K), δ ppm (relative to



TFA –76.55 ppm): –71.80 (s). ^{13}C -NMR (150 MHz, δ ppm from 2D HSQC and 2D HMBC, DMSO-d₆, 300 K): 184.3 (C2'), 182.8 (C2), 171.7 (C18), 168.0 (C13), 149.8 (overlapping C7, C8, C8'), 148.5 (C7'), 141.4 (C4'), 140.2 (C4), 129.4 (C5), 126.8 (C5'), 123.8 (C10'), 123.1 (C3), 122.9 (C10), 121.6 (C3'), 116.2 (C9'), 114.5 (C9), 111.8 (C6'), 111.6 (C6), 101.3 (C1), 68.9 (C22), 68.2 (C12), 56.3 (overlapping C26, C26'), 52.3 (C15), 35.3 (C20), 32.03 (C17), 29.9 (C21), 27.7 (C16). ESI-MS (m/z): calcd: for C₃₅H₃₅F₉N₂O₁₁ [M + H]⁺ 831.21 found: 831.24; [M + Na]⁺ 753.14, [M + 2H]⁺ 416.32.

Synthesis of disubstituted curcumin derivatives (Cure-C₆-F18, Cure-Glu-F18)

Compound **Cure-C₆-F18** and **Cure-Glu-F18** were obtained by performing the same procedure, starting from bis-NHS ester of curcumin (compound **3b**, 0.7 g, 0.11 mmol) and perfluoroamine derivatives (0.25 mmol).

Cure-C₆-F18: (0.06 g). Yield: 48%, t_{R} 8.73 min, 96% purity. ^1H -NMR (CD₃CN, 600 MHz, 310 K), δ ppm: 7.60 (d, J = 15.9 Hz, 2H, H4), 7.30 (s, 2H, H6), 7.19 (d, J = 8.0 Hz, 2H, H10), 7.01 (t, br, 2H, H14), 6.95 (d, J = 8.0 Hz, 2H, H9), 6.75 (d, J = 15.9 Hz, 2H, H3), 5.95 (s, 1H, H1), 4.50 (s, 4H, H12), 4.05 (t, J = 5.6 Hz, 4H, H20), 3.91 (s, 6H, H23), 3.22 (q, J = 6.6 Hz, 4H, H15), 1.64 (m, 4H, H19), 1.48 (m, 4H, H16), 1.37 (m, 4H, H18), 1.29 (m, 4H, H17) (see ESI section 2.10† for details and NMR assignment). ^{19}F -NMR (470 MHz, ethanol/DMSO-d₆, 550 : 50, 298 K), δ ppm (relative to TFA –76.55 ppm): –71.84 (s). ESI-MS (m/z): calcd: for C₄₅H₄₈F₁₈N₂O₁₀ [M + 2H]²⁺ 560.19, found: 560.25.

Cure-Glu-F18: (0.06 g). Yield: 32%, t_{R} 5.08 min, 98% purity. ^1H -NMR (600 MHz, DMSO-d₆, 300 K), δ ppm: 8.29 (d, J = 7.7 Hz, 2H, H14), 7.92 (t, J = 5.6 Hz, 2H, H19), 7.62 (d, J = 15.8 Hz, 2H, H4), 7.43 (d, J = 1.5 Hz, 2H, H6), 7.27 (dd, J = 8.4 and 1.5 Hz, 2H, H10), 7.01 (d, J = 8.4 Hz, 2H, H9), 6.90 (d, J = 15.8 Hz, 2H, H3), 6.15 (s, 1H, H1), 4.65 (AB system, 4H, H12), 4.30 (m, 2H, H15), 4.11 (t, J = 6.2 Hz, 4H, H22), 3.91 (s, 6H, H26), 3.15 (m, 4H, H20), 2.17 (m, 4H, H17), 2.06 (m, 2H, H16a), 1.88 (m, 2H, H16b), 1.82 (m, J = 6.5 Hz, 4H, H21) (see ESI section 2.11† for details and NMR assignment). ^{19}F -NMR (470 MHz, ethanol/DMSO-d₆, 550 : 50, 298 K), δ ppm (relative to TFA –76.55 ppm): –71.72 (s). ESI-MS (m/z): calcd: for C₄₉H₅₀F₁₈N₄O₁₆ [M + 2H]²⁺ 647.14, found: 647.39.

In vitro assays

Stock solutions of the ^{19}F -labelled curcumin probes were prepared by dissolving the required mass of the probe into 5 mL of analytical grade ethanol to obtain a concentration in the 0.5–3.0 mM range. The exact concentration of stock solutions was assessed by quantitative ^{19}F -NMR spectroscopy (qNMR, see ESI section 1.2†).

Preparation of amyloid-beta (A β) aggregates

5 mg of A β (1–42) (Anaspec) lyophilized powder were solubilized in 7 mL HFIP (hexafluoro-2-propanol), portioned, evaporated ON at room temperature and stored at –20 °C.

An A β aliquot (45 μ g) was solubilized in 20 μ L of a freshly prepared mixture consisting of CH₃CN/300 μ M Na₂CO₃/

250 mM NaOH (48.3/48.3/3.4, v/v/v) to obtain a 500 μ M stock solution (pH 13). The stock solution was sonicated in a water bath to remove preformed aggregates. The A β peptide solution was diluted 1 : 10 (v/v) in phosphate buffer 10 mM pH 7.4 containing 11 mM NaCl²² and then incubated at 4 °C, no stirring for 24 hours to have A β oligomers,³¹ or at 37 °C, 600 rpm for 4 days to have A β aggregates in protofibrillar and fibrillar state.

Field emission scanning electron microscopy (FESEM)

Morphological analysis of A β aggregates was performed by FESEM. After 5 days of incubation, the samples are diluted to remove excess salts, centrifuged and the supernatant removed. The pellet was resuspended in pure water and 10 μ L of this solution was spotted onto a gold-coated glass coverslip. To assess fibril morphology, images of the samples are acquired using a Tescan FEG-SEM S9000. Measurements are acquired with a Schottky emitter, the probe set at 100 pA and the electron beam energy at 5 keV. The analysis was performed with an in-beam SE detector. Microanalysis was performed using OXFORD – Ultim Max detector – AZTEC software.

Binding assay to amyloid-beta (A β) aggregates

The fluorometric assays were performed with a Horiba Jobin Yvon spectrofluorometer Fluoromax-4 (Kyoto, Japan). Stock solution (3 mM) of commercial curcumin, **Cure-C₃-F9**, **Cure-C₆-F9**, **Cure-Glu-F9**, **Cure-C₆-F18**, **Cure-Glu-F18** were prepared in 99% (v/v) ethanol. The assay was performed using a fixed concentration of reporter ligand (between 20–30 nM) and varying concentrations of A β aggregates (0–3.3 μ M). After 4 days of incubation, the A β solutions (50 μ M) were diluted with phosphate buffer 10 mM pH 7.4 plus 11 mM NaCl and 0.5% ethanol, containing the reporter ligand, up to a final volume of 2.0 mL. The fluorescence emission signal was monitored at 495, 497 nm, or 488 nm ($\lambda_{\text{ex}} = 450$ nm) with excitation and emission slits of 5 nm bandwidth. An emission calibration curve for each compound was prepared to determine their molar fluorescence emission observed when the compound is unbound. From the plot of the S1/R1 fluorescent emission at the respective wavelength, fitted by using [eqn (1)], it was possible to obtain a thermodynamic dissociation constant assuming a 1 : 1 interaction with A β .

$$y = \frac{(K_a C_t + nxK_a + 1) - \sqrt{(K_a C_t + nxK_a + 1)^2 - 4K_a^2 C_t nx}}{2K_a} \quad (1)$$

$$\times (F_b - F_f) + F_f \times C_t + F_{\text{pr}} x + \text{BKG}$$

K_a = association constant, C_t = compound fixed concentration, n = number of binding sites, x = A β concentration, F_b = molar fluorescence intensity observed at the peak of the emission spectra when the compound is bound to fibrils, F_f = molar fluorescence intensity observed at the peak of the emission spectra when the compound is free, F_{pr} = molar fluorescence emission observed at the peak of the emission spectra for A β aggregates, BKG = background fluorescence (buffer plus 0.5% ethanol).



Human serum albumin (HSA) binding assay

The fluorometric assays were performed with a Shimadzu RF-6000. Stock solution (3 mM) of commercial curcumin, **Cure-C₃-F9**, **Cure-C₆-F9**, **Cure-Glu-F9**, **Cure-C₆-F18**, **Cure-Glu-F18** were prepared in 99% (v/v) ethanol. The assay was performed using a fixed concentration of reporter ligand (about 30 nM) and varying concentrations of HSA (0–27 μ M) (lyophilized powder, \geq 96% (agarose gel electrophoresis), purchased from Sigma-Aldrich). The HSA stock solution (2 mg mL⁻¹) was diluted with phosphate buffer 10 mM pH 7.4 plus 11 mM NaCl and 0.5% ethanol, containing the reporter ligand, up to a final volume of 2.0 ml. The fluorescence emission signal was monitored at 485 nm ($\lambda_{\text{ex}} = 430$ nm) with excitation and emission slits of 5 nm bandwidth. The plot of the S1 fluorescent emission at 485 nm vs. HSA concentration was fitted by using [eqn (1)] substituting HSA to A β thus obtaining the thermodynamic association constant assuming a 1 : 1 interaction with the protein.

Solubility test in physiological buffer

Solubility tests were carried out by solubilizing the compound in NaCl/HEPES buffer (4,2-hydroxyethyl-1-piperazineethanesulfonic acid) at 300 mOsm with a concentration of 4.5 mM of each compound. It was decided to operate at a surfactant concentration of CREMOPHOR EL ranging from 10% to 20% v/v, depending on the compound's degree of lipophilicity and behavior during the test. To aid solubilization, the solutions were sonicated (40 kHz) for 5 minutes at 30 °C between each buffer addition. Finally, the pH of the mixture was monitored using a pH meter and maintained at a value of 7.4 (physiological pH).

Longitudinal and transverse (T_1 and T_2) relaxation times measurements

To measure the longitudinal (T_1) and transverse (T_2) ¹⁹F-NMR relaxation times, **Cure-Glu-F9** and **Cure-Glu-F18** were solubilized in NaCl/HEPES buffer (300 mOsm) + 10% v/v CREMOPHOR EL, while **Cure-C₆-F9** in NaCl/HEPES buffer (300 mOsm) + 20% v/v CREMOPHOR EL. Measurements were conducted at room temperature by means of a Bruker Avance microimaging scanner operating at 7 T, corresponding to 300 and 282 MHz proton and ¹⁹F Larmor frequency, respectively. The scanner was equipped with a 40 mm ¹H/¹⁹F volume transmit-receive probe. T_1 was measured by inversion recovery with repetition time = 5 s, number of averages = 10, number of variable delays = 16. T_2 was measured by means of the CPMG pulse sequence, with the same parameters as above and an echo time of 0.0002 s.

MRI image acquisition

Experiments were conducted at room temperature using the Bruker Avance 300 MHz magnet (7 T), equipped with a 40 mm ¹H/¹⁹F volume transmit-receive probe. Samples were solubilized as previously reported at a concentration of 4.5 mM. First, a T_2 -weighted ¹H image was acquired to localize the samples with the following parameters: echo time (ms): 72.79, rep-

etition time (s): 4, rare factor: 32, matrix: 256 \times 256, FOV (cm): 3.5 \times 3.5, slice thickness (mm): 3, acquisition time (min): 1.40. Then a ¹⁹F MR image was acquired with the following parameters: SFO1 (MHz) 282.3903307, echo time (ms): 3, repetition time (s): 1, rare factor: 24, matrix: 32 \times 32, FOV (cm): 3.5 \times 3.5, slice thickness (mm): 3: number of averages: 630, acquisition time (min): 10.30. The signal to noise ratio (SNR) for each sample was calculated using the formula:

$$\text{SNR} = \frac{(S_{\text{sample}} - S_{\text{H}_2\text{O}})}{\text{SD}_{\text{noise}}}$$

Here, S_{sample} represents the average ¹⁹F signal measured within a specific region of interest (ROI) for each sample, $S_{\text{H}_2\text{O}}$ is the average ¹⁹F signal measured in a control sample without fluorine, and SD_{noise} denotes the standard deviation of the ¹⁹F signal measured in the background of the image, capturing the statistical intensity distribution of the noise.

¹⁹F-NMR spectroscopy

¹⁹F-NMR spectroscopy to study the interaction between the fluorinated curcumin derivatives and A β aggregates was performed with a Bruker AvanceNeo 9.4 T NMR spectrometer (376 MHz, ¹⁹F Larmor frequency). A stock solution (3 mM) of **Cure-Glu-F9** was prepared in 99% (v/v) ethanol. The A β aggregates samples (monomers, oligomers and fibrils) were diluted with phosphate buffer 10 mM pH 7.4 plus 11 mM NaCl, 16% D₂O and 3.5% ethanol, containing the fluorinated compound, up to a final volume of 0.3 ml. The NMR spectra were acquired at 298 K using the following parameters: spectral width (sw) 30 120.482 Hz, relaxation delay (d1) 2.5 s, number of scans (ns) 256–512.

Author contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Data availability

The data supporting this article have been included in the text and in the ESI.†

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 964934, Nectar project. The authors acknowledge the Italian Ministry of Research for FOE contri-



bution to the EuroBioImaging MultiModal Molecular Imaging Italian Node (<https://www.mmmi.unito.it>). G. D. acknowledges MUR PRIN 2022 funding (project 2022598YAX, OPTIMA). F. G. acknowledges financial support from PON Ricerca e Innovazione 2014–2020, Action IV.6. Maria Carmen Valsania and Erica Rebba are acknowledge for the acquisition of FESEM images at the Chemistry Department of the University of Turin.

References

- 1 (a) R. U. Haquea and A. I. Levey, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**(52), 26224–26229; (b) A. Serrano-Pozo, M. P. Frosch, E. Masliah and B. T. Hyman, *Cold Spring Harbor Perspect. Med.*, 2011, **1**(1), a006189.
- 2 (a) J. Hardy and D. J. Selkoe, *Science*, 2002, **297**, 353–356; (b) J. Lewis, D. W. Dickson, W. L. Lin, L. Chisholm, A. Corral, G. Jones, S. H. Yen, N. Sahara, L. Skipper, D. Yager, C. Eckman, J. Hardy, M. Hutton and E. McGowan, *Science*, 2001, **293**(5534), 1487–1491.
- 3 (a) W. F. Xue, A. L. Hellewell, E. W. Hewitt and S. E. Radford, *Prion*, 2010, **4**, 20–25; (b) J. C. Lee, S. J. Kim, S. Hong and Y. Kim, *Exp. Mol. Med.*, 2019, **51**, 1–10.
- 4 X. Zhang and C. Ran, *Curr. Org. Chem.*, 2013, **17**(6), 580–593.
- 5 F. Yang, G. P. Lim, A. N. Begum, O. J. Ubeda, M. R. Simmons, S. S. Ambegaokar, C. Pingping, K. Rakez, C. G. Glabe, S. A. Frautschy and G. M. Cole, *J. Biol. Chem.*, 2005, **280**, 5892–5901.
- 6 G. Si, S. Zhou, G. Xu, J. Wang, B. Wu and S. Zhou, *Dyes Pigm.*, 2019, **163**, 509–515.
- 7 G. P. Lim, T. Chu, F. Yang, W. Beech, S. A. Frautschy and G. M. Cole, *J. Neurosci.*, 2001, **21**(21), 8370–8377.
- 8 V. L. Villemagne, V. Dore, P. Bourgeat, S. C. Burnham, S. Laws, O. Salvado, C. L. Masters and C. C. Rowe, *Semin. Nucl. Med.*, 2017, **47**, 75–88.
- 9 W. E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D. P. Holt, M. Bergström, I. Savitcheva, G. F. Huang, S. Estrada, B. Ausén, M. L. Debnath, J. Barletta, J. C. Price, J. Sandell, B. J. Lopresti, A. Wall, P. Koivisto, G. Antoni, C. A. Mathis and B. Långström, *Ann. Neurol.*, 2004, **55**(3), 306–319.
- 10 W. Zhang, S. Oya, M. P. Kung, C. Hou, D. L. Maier and H. F. Kung, *J. Med. Chem.*, 2005, **48**(19), 5980–5988.
- 11 (a) E. K. Degenhardt, M. M. Witte, M. G. Case, P. Yu, D. B. Henley, H. M. Hochstetler, D. N. D'Souza and P. T. Trzepacz, *Psychosomatics*, 2016, **57**, 208–216; (b) L. Filippi, A. Chiaravalloti, O. Bagni and O. Schillaci, 18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease, *Am. J. Nucl. Med. Mol. Imaging*, 2018, **8**, 268–281.
- 12 D. Yanagisawa, T. Amatsubo, S. Morikawa, H. Taguchi, M. Urushitani, N. Shirai, K. Hirao, A. Shiino, T. Inubushi and I. Tooyama, *Neuroscience*, 2011, **184**, 120–127.
- 13 D. Yanagisawa, H. Taguchi, S. Morikawa, T. Kato, K. Hirao, N. Shirai and I. Tooyama, *Biochem. Biophys. Rep.*, 2015, **4**, 357–368.
- 14 I. Tooyama, D. Yanagisawa, H. Taguchi, T. Kato, K. Hirao, N. Shirai, T. Sogabe, N. F. Ibrahim, T. Inubushi and S. Morikawa, *Ageing Res. Rev.*, 2016, **30**, 85–94.
- 15 D. Yanagisawa, N. Shirai, T. Amatsubo, H. Taguchi, K. Hirao, M. Urushitani, S. Morikawa, T. Inubushi, M. Kato, F. Kato, K. Morino, H. Kimura, I. Nakano, C. Yoshida, T. Okada, M. Sano, Y. Wada, K. Wada, A. Yamamoto and I. Tooyama, *Biomaterials*, 2010, **31**(14), 4179–4185.
- 16 D. Yanagisawa, N. F. Ibrahim, H. Taguchi, S. Morikawa, T. Tomiyama and I. Tooyama, *Molecules*, 2021, **26**(5), 1362.
- 17 T. Amatsubo, S. Morikawa, T. Inubushi, M. Urushitani, H. Taguchi, N. Shirai, K. Hirao, M. Kato, K. Morino, H. Kimura, I. Nakano, C. Yoshida, T. Okada, M. Sano and I. Tooyama, *Neurosci. Res.*, 2009, **63**(1), 76–81.
- 18 E. Chainoglou and D. H. Litina, *Int. J. Mol. Sci.*, 2020, **21**(6), 1975.
- 19 G. Schitter, A. J. Steiner, G. Pototschnig, E. Scheucher, M. Thonhofer, C. A. Tarling, S. G. Withers, K. Fantur, E. Paschke, D. J. Mahuran, B. A. Rigat, M. B. Tropak, C. Illaszewicz, R. Saf, A. E. Stütz and T. M. Wrodnigg, *ChemBioChem*, 2010, **11**(14), 2026–2033.
- 20 S. Nasir Abbas Bukhari and I. Jantan, *Mini-Rev. Med. Chem.*, 2015, **15**(13), 1110–1121.
- 21 B. Laha, A. R. Tiwari, E. Gravel, E. Doris and I. N. N. Namboothiri, *Org. Biomol. Chem.*, 2024, **22**(7), 1346–1359.
- 22 A. De Simone, M. Naldi, D. Tedesco, A. Milelli, M. Bartolini, L. Davani, D. Widera, M. L. Dallas and V. Andrisano, *ACS Omega*, 2019, **4**(7), 12308–12318.
- 23 M. Groenning, *J. Chem. Biol.*, 2010, **3**(1), 1–18.
- 24 (a) G. Si, S. Zhou, G. Xu, J. Wang, B. Wu and S. Zhou, *Dyes Pigm.*, 2019, **163**, 509–515; (b) J. Den Haan, T. H. J. Morrema, A. J. Rozemuller, F. H. Bouwman and J. J. Hoozemans, *Acta Neuropathol. Commun.*, 2018, **6**(1), 75.
- 25 (a) K. I. Priyadarsini, Photophysics, *J. Photochem. Photobiol. C*, 2009, **10**(2), 81–95; (b) A. Barik, K. I. Priyadarsini and H. Mohan, *Photochem. Photobiol.*, 2007, **77**(6), 597–603.
- 26 Z. Qia, M. Wua, Y. Fua, T. Huang, T. Wanga, Y. Suna, Z. Fengc and C. Lia, *Cell. Physiol. Biochem.*, 2017, **44**, 618–633.
- 27 A. Barik, B. Mishra, A. Kunwar and K. I. Priyadarsini, *Chem. Phys. Lett.*, 2007, **436**, 239–243.
- 28 Y. W. Kim, K. N. Chung, H. S. Kang and Y. Y. Sheen, *Biomol. Ther.*, 2008, **16**(1), 40–45.
- 29 (a) Y. C. Youn, B. S. Lee, G. J. Kim, J. S. Ryu, K. Lim, R. Lee, J. Suh, Y. H. Park, J. M. Pyun, N. Ryu, M. J. Kang, H. R. Kim, S. Kang, S. S. A. An and S. Kim, *J. Alzheimer's Dis.*, 2020, **75**, 493–499; (b) S. M. Wang, D. W. Kang, Y. H. Um, S. Kim, C. U. Lee, P. Scheltens and H. K. Li, *Alzheimer's Res. Ther.*, 2024, **16**(1), 55.
- 30 H. Amiri, M. Srinivas, A. Veltien, M. J. van Uden, J. M. de Vries and A. Heerschap, *Eur. Radiol.*, 2015, **25**, 726–735.
- 31 W. B. Stine, K. N. Dahlgren, G. A. Krafft and M. J. LaDu, *J. Biol. Chem.*, 2003, **278**, 11612–11622.

